Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial

20260 citationsJournal Articlehybrid Open Access

Authors

BVd demonstrated manageable safety and clinical activity across all dosing cohorts in heavily pretreated RRMM, supporting the 2.5 mg/kg Q3W dose.

Good health and well-being

Published in: Clinical Cancer Research

Field-Weighted Citation Impact: 0.00